Preliminary results from three clinical trials reveal some benefits of cetuximab plus irinotecan, amivantamab plus FOLFOX or FOLFIRI and ramucirumab plus standard of care for patients with mCRC, including after progression on standard therapies
Three-year disease-free survival data from NICHE-2 and findings from NICHE-3 add to current knowledge on the benefits of immune checkpoint inhibition in this setting
Data from clinical trials show the value of liquid biopsy in treatment decision-making and prognostication
Lessons learned about the importance of the gut microbiome composition in immune checkpoint inhibitor therapy response could be crucial in tailoring cancer care
In the TRANSMET trial, a 5-year overall survival benefit was observed in a highly selected patient population
Recent data indicate a role of immunotherapy for tumours with high levels of microsatellite instability, especially in the neoadjuvant setting
Research is moving forward to adapt clinical practice to a new wave of early-onset cases of cancer in the digestive tract
Safety and efficacy data of a PD-1/IL-2 bispecific antibody fusion protein were presented at an ESMO Virtual Plenary
Recent results from research have changed the treatment paradigm for some digestive tumours, but further evidence is needed to finetune the neoadjuvant approach
While novel agents continue to enrich the therapeutic armamentarium in this setting, patients ask for a longer survival, but also for a better quality of life
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.